291 related articles for article (PubMed ID: 18996314)
1. Dendritic cell vaccines for the treatment of prostate cancer.
Lehrfeld TJ; Lee DI
Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
[TBL] [Abstract][Full Text] [Related]
2. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
5. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with dendritic cells for cancer.
Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
[TBL] [Abstract][Full Text] [Related]
8. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Arlen PM; Gulley JL; Tsang KY; Schlom J
Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
[TBL] [Abstract][Full Text] [Related]
9. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of dendritic cell vaccines.
Morse MA; Lyerly HK
Curr Opin Mol Ther; 2000 Feb; 2(1):20-8. PubMed ID: 11249649
[TBL] [Abstract][Full Text] [Related]
11. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccines for prostate cancer: a review of clinical data.
Arlen PM; Gulley JL
Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
[TBL] [Abstract][Full Text] [Related]
13. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.
Matera L
Cancer Treat Rev; 2010 Apr; 36(2):131-41. PubMed ID: 19954892
[TBL] [Abstract][Full Text] [Related]
14. DC therapy for prostate cancer.
Swindle PW; Tepes S; Clements J
Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
[TBL] [Abstract][Full Text] [Related]
15. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
Qi SY; Wang M; Xu Y
Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
[TBL] [Abstract][Full Text] [Related]
16. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
[TBL] [Abstract][Full Text] [Related]
17. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell vaccines in acute leukaemia.
Duncan C; Roddie H
Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
[TBL] [Abstract][Full Text] [Related]
19. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
Lin AM; Hershberg RM; Small EJ
Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
